Market Overview

UPDATE: Stifel Nicolaus Raises PT to $9 on Boston Scientific Corporation Post Analyst Day

Related BSX
Morgan Stanley Reviews Boston Scientific Q3 Results
UPDATE: Boston Scientific Posts In-Line Q3 Profit, Raises Forecast

Stifel Nicolaus maintained Boston Scientific Corporation (NYSE: BSX) with a Buy rating and raised the price target from $8.00 to $9.00.

Stifel Nicolaus noted, "We left yesterday's Boston Scientific New York Analyst Day believing our basic thesis on BSX shares is unchanged. If anything, we left with increased conviction that after three years of negative top-line growth, BSX now has in place multiple avenues to re-accelerate sales growth back to mid-single digits by the 2016-2017 time frame. … Also evident throughout the meeting was the strong management team now in place at BSX and their clear and energetic strategic vision for the company. Overall, management laid out what we thought was a well thought-out and realistic plan to improve the growth and profitability prospects of the company."

Boston Scientific Corporation closed at $7.59 on Tuesday.

Latest Ratings for BSX

DateFirmActionFromTo
Sep 2014NeedhamInitiates Coverage onHold
Jul 2014Sterne AgeeInitiates Coverage onNeutral
Jul 2014BarclaysMaintainsOverweight

View More Analyst Ratings for BSX
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Analyst Ratings

 

Related Articles (BSX)

Around the Web, We're Loving...

Get Benzinga's Newsletters